Strategic partnerships to develop novel therapeutics.

At PTC, we are committed to discovering, developing and commercializing therapeutics that address disorders with high unmet medical needs. Strategic collaborations provide expanded opportunities to apply PTC's scientific approach to additional therapeutic areas. We seek alliances and partnerships with leading biopharmaceutical and advocacy groups.

We have a collaboration with Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., to commercialize two of Akcea's rare disease drugs in Latin America (LATAM): TEGSEDI™ (inotersen) and WAYLIVRA™ (volanesorsen).  We currently have ongoing collaborations with Roche and the SMA Foundation for the development and commercialization of compounds for the treatment of spinal muscular atrophy. We have received grant funding from the Wellcome Trust for the research and development of small molecule compounds that selectively decrease the production of BMI1 expression in tumor stem cells.

By selecting Confirm, you are leaving the PTC Therapeutics U.S. website. This external link is provided for your convenience. Please note that external links or web sites may not be controlled by PTC Therapeutics, and thus not subject to our Privacy policy and Terms of use.

Thank you for visiting our site.
Cancel Confirm
This site uses cookies to store information on your computer.
Cancel Continue